Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Satelli, Arun ^a   Batth, Izhar Singh ^a   Brownlee, Zachary ^a   Rojas, Christina ^a   Meng, Qing H ^a   Kopetz, Scott ^a   Li, Shulin ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; VIMENTIN;

BLOOD; CELL NUCLEUS; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; NEOPLASM; PROGNOSIS; PROSTATE TUMOR; RETROSPECTIVE STUDY; TUMOR EMBOLISM;

B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CELL NUCLEUS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HCT116 CELLS; HEK293 CELLS; HUMANS; MALE; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; VIMENTIN;

EID: 84976877484     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28910     Document Type: Article

References (26)

1. Satelli, A. et al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21, 899-906 (2015).
2. Satelli, A. et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74, 1645-1650 (2014).
3. Pantel, K., Alix-Panabieres, C. The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov 2, 974-975 (2012).
4. Lowes, L. E. et al. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy. Prostate Cancer Prostatic Dis 18(4), 358-64 (2015).
5. Ren, C. et al. Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy. Int J Cancer 138(7), 1586-600 (2016).
6. Agelaki, S. et al. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. PLoS One 10, e0123683 (2015).
7. Dorsey, J. F. et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer 121, 139-149 (2015).
8. Bertucci, F. et al. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology 4, e1002729 (2015).
9. Bertucci, F. et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 6, 13506-13519 (2015).
10. Sabatier, R. et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 6, 5449-5464 (2015).
11. Hasan, A., Ghebeh, H., Lehe, C., Ahmad, R., Dermime, S. Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets 15, 1211-1225 (2011).
12. Wu, P., Wu, D., Li, L., Chai, Y., Huang, J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One 10, e0131403 (2015).
13. Mazel, M. et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9, 1773-1782 (2015).
14. Ghebeh, H. et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res 12, R48 (2010).
15. Satelli, A., Brownlee, Z., Mitra, A., Meng, Q. H., Li, S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule-and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem 61, 259-266 (2015).
16. Pantel, K., Speicher, M. R. The biology of circulating tumor cells. Oncogene, doi: 10.1038/onc (2015).
17. McInnes, L. M. et al. Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol, doi: 10.3389 (2015).
18. Liu, H. et al. The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol 141, 189-201 (2015).
19. Mitra, A., Mishra, L., Li, S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6, 10697-10711 (2015).
20. Bill, R., Christofori, G. The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett 589, 1577-1587 (2015).
21. Zoni, E., van der Pluijm, G., Gray, P. C., Kruithof-de Julio, M. Epithelial Plasticity in Cancer: Unmasking a MicroRNA Network for TGF-beta-, Notch-, and Wnt-Mediated EMT. J Oncol 198967 (2015).
22. Beije, N., Jager, A., Sleijfer, S. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer Treat Rev 41, 144-150 (2015).
23. Adams, D. L. et al. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch((R)) CTC test. Cytometry A 87, 137-144 (2015).
24. Truini, A. et al. Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. Front Oncol 4, 242 (2015).
25. Raimondi, C., Gradilone, A., Naso, G., Cortesi, E., Gazzaniga, P. Clinical utility of circulating tumor cell counting through CellSearch((R)): the dilemma of a concept suspended in Limbo. Onco Targets Ther 7, 619-625 (2014).
26. Ingebrigtsen, V. A. et al. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer 131, 2528-2536 (2012).